Critical Outcome Technologies Inc. home page
HOME COTI-2 PARTNERING PIPELINE CHEMSAS INVESTORS ABOUT US CONTACT


Critical Outcome Technologies Inc. (COTI) is helping the pharmaceutical industry get novel treatments to market faster.

At COTI’s core is a proprietary technology called CHEMSAS® that rapidly accelerates drug discovery. COTI is able to discover, profile, optimize, synthesize and validate novel compounds in 12-15 months. The current industry approach can take up to 60 months.

Our products are targeted libraries of novel, optimized lead compounds for the treatment of human diseases for which current therapy is either lacking or ineffective. Learn more about our pipeline.

Visit our partnering page if you are interested in augmenting your existing pipeline or developing a pipeline in areas of interest and reducing the cost of drug discovery.

9.10.14

Selective and Potent Anti-Cancer p53-Dependent Activity Demonstrated by Critical Outcome's COTI-2

9.8.14

Critical Outcome Technologies and UT MD Anderson Cancer Center Sign Letter of Intent for Phase 1 Development of COTI-2

8.22.14

Notice of Annual General and Special Meeting 2014

 

Our Products

Become a Partner

Investor News

Careers

 
 
© 2014 Critical Outcome Technologies Inc. All rights reserved.